VSTM Verastem, Inc.

+0.05  (2%)
Previous Close 2.32
Open 2.32
Price To book 1.42
Market Cap 87.67M
Shares 36,992,000
Volume 330,297
Short Ratio 0.46
Av. Daily Volume 471,795

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 initiation of dosing announced January 26, 2017.
Avelumab and defactinib
Ovarian cancer
Phase 1b/2 trial initiated 1H 2016
Duvelisib and venetoclax
Relapsed or refractory CLL, small lymphocytic lymphoma, iNHL or aggressive NHL cancer
Phase 1/2 initial data - 21st Congress of European Hematology Association June 9 - 12, 2016
Duvelisib - Conetempo
Treatment-naïve patients with follicular lymphoma
Phase 2 data released June 2016 - short of expectations
Duvelisib (IPI-145) DYNAMO
Indolent non-Hodgkin lymphoma
Phase 3 data due mid-2017.
Duvelisib - DUO
Cancer - relapsed/refractory chronic lymphocytic leukemia (CLL)
Phase 2 interim analysis showed lack of efficacy. Trial stopped. September 2015
Mesothelioma prior to surgery
Phase 2 failed to meet endpoint - Jan 2015
Duvelisib (IPI-145)
Rheumatoid arthritis

Latest News

  1. Verastem Reports Phase 2 Long-Term Follow-Up Data for Duvelisib in Patients with Double-Refractory Follicular Lymphoma and Small Lymphocytic Lymphoma at the 22nd Congress of the European Hematology Association
  2. Verastem to Present Long-Term Follow-Up Data from the DYNAMO™ Study at the 14th International Conference on Malignant Lymphoma
  3. Notes From ASCO 2017: Tesaro, Amgen, Others Report New Data
  4. Verastem to Present at the Jefferies 2017 Global Healthcare Conference
  5. Verastem Announces Duvelisib Data Presentations at the 22nd Congress of the European Hematology Association
  6. Today's Research Reports on Stocks to Watch: Array Biopharma and Verastem
  7. Verastem reports 1Q loss
  8. Verastem Reports First Quarter 2017 Financial Results
  9. BioXcel Therapeutics, Inc. (BTI) Is Launched with Phase 2-ready Programs Addressing Unmet Needs in Immuno-oncology and Neuroscience
  10. Verastem Announces Long Term Follow-up Data from the DYNAMO Study Selected for Oral Presentation at the 14th International Conference on Malignant Lymphoma
  11. Verastem Appoints Eric K. Rowinsky to the Board of Directors
  12. Today's Research Reports on Biotech Stocks to Watch: Ocera Therapeutics and Verastem
  13. Verastem to Present at the 16th Annual Needham Healthcare Conference
  14. Data on Verastem’s Focal Adhesion Kinase Inhibitor Defactinib Presented at the 2017 American Association for Cancer Research Annual Meeting
  15. Verastem Reports Year-End 2016 Financial Results
  16. Verastem to Host Conference Call on March 23rd to Discuss Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights
  17. Verastem to Present at the Oppenheimer 27th Annual Healthcare Conference
  18. Verastem to Present at the 29th Annual ROTH Conference
  19. Verastem to Present at 19th Annual BIO CEO & Investor Conference